CTOs on the Move

Biogen

www.biogen.com

 
We are a biotechnology leader that discovers, develops and delivers innovative therapies to improve the lives of patients with neurodegenerative diseases, hematologic conditions and autoimmune diseases. Patients worldwide benefit every day from our medicines for multiple sclerosis (MS) and hemophilia.
 Founded in 1978, we are one of the world’s oldest independent biotechnology companies. Our development pipeline is focused on areas of high unmet medical need, as we pursue new therapies for patients suffering from diseases with few or no treatment options. These include programs for secondary progressive MS, Alzheimer’s Disease, spinal muscular atrophy, lupus and amyotrophic lateral sclerosis (ALS), amongst others. With ...
  • Number of Employees: >100K
  • Annual Revenue: > $1 Billion
  • www.biogen.com
  • 225 Binney Street
    Cambridge, MA USA 02142
  • Phone: 781.464.2000

Executives

Name Title Contact Details
Richard Nolan
 Deputy Chief Information Security Officer Profile
Dave Clifford
 Head of Technology and AI, BDH Data Profile
Pietr Lindahl
 Deputy Chief Information Security Officer Profile
Keith Sarbaugh
 Vice President, IT Infrastructure, Architecture and Operations Profile
Chris Fahey
 Director of Security Operations Profile

Similar Companies

Amira Pharmaceuticals

Amira Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synsorb Biotech

Synsorb Biotech Inc. is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Forty Seven

With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.

Okogen

Okogen serves the needs of adults and children with ocular infections by developing therapies to reduce suffering, improve quality of life, and preserve vision.

Autolus

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.